German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy.
Kye Pharmaceuticals (“Kye”) announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback